Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal

Opioid Use Clinical Trial

— UH3  

Official title:

Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05995535
• Other study ID #: 854046
• Status: Recruiting
• Phase: Phase 2
• Start date: January 1, 2024
• Est. completion date: August 31, 2026

Study information

• Verified date: January 2024
• Source: University of Pennsylvania
• Contact: Kyle M Kampman, MD
• Phone: 215-746-2764
• Email: Kampman[@]pennmedicine.upenn.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A placebo-controlled trial in which male and female outpatients with an opioid use disorder who express interest in extended-release injectable naltrexone (XR-NTX) are randomized 1:1 to lofexidine/pregabalin or lofexidine/pregabalin placebo for withdrawal management and offered XR-NTX if after completing withdrawal.

Description:

A placebo-controlled trial in which male and female outpatients with an opioid use disorder who express interest in extended-release injectable naltrexone (XR-NTX) are randomized 1:1 to lofexidine/pregabalin or lofexidine/pregabalin placebo for withdrawal management and offered XR-NTX if after completing withdrawal. It follows a UG3 study in which 90 inpatients with an OUD who expressed interest in XR-NTX were randomized 2:1 to withdrawal management with lofexidine/pregabalin or lofexidine/placebo pregabalin. Results were that the conditions were equally safe, and that lofexidine/pregabalin was more effective in reducing subjective withdrawal and keeping patients in treatment than lofexidine/placebo pregabalin. The objectives are to study the safety and effectiveness of lofexidine/pregabalin compared to lofexidine/placebo for managing opioid withdrawal and transitioning to XR-NTX in outpatient settings.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: August 31, 2026
• Est. primary completion date: August 31, 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male and/or female subjects = 18 years of age

2. Meet DSM-5 criteria for an Opioid Use Disorder with physiologic features. Have met 2 or more of the 11 criteria for an OUD including tolerance and withdrawal within the last 12 months

3. Interested in opioid antagonist treatment

4. Used opioids in 20 or more of the last 30 days

5. A stable address in the local area; not planning to move in the next 60 days.

6. Have documents for ID check

7. Absence of medical or psychiatric conditions that are likely to interfere with study participation

8. Has 12 lead ECG demonstrating a QTc =450 msec and a QRS =120 msec. Site PI has final determination for study inclusion if readings exceed these limits. The PENN cardiologists and medical monitor are available for consultation when needed

9. Negative pregnancy test and using adequate contraception if of childbearing potential.

Exclusion Criteria:

1. Current psychotic disorder (bipolar I, schizophrenia, major depression that is not in remission

2. Alcohol, benzodiazepine, or other sedative use disorder with physiological features that require medication for detoxification

3. Allergy or other serious adverse event due to treatment with pregabalin, XR-NTX, or lofexidine

4. Pending incarceration or plans to leave the immediate area in the next 30 days

5. Homicidal or otherwise behaviorally disturbed requiring immediate attention

6. High risk for suicide as determined by answering 'yes' to questions 4 and/or 5 on C-SSRS

7. Blood pressure <90 mm Hg (systolic) or <60 mm Hg (diastolic). If value out of normal range, the investigator and study Clinician will decide subject inclusion/exclusion on case-by-case basis

8. Heart rate and/or pulse<50 bpm at screening-sitting

9. An Estimated Glomerular Filtration Rate eGFR<70 mL/min/1.73m2

10. A History of, or current Seizure disorder (excluding childhood febrile seizures)

11. Inability to read and/or understand English. For example, unable to understand the informed consent as demonstrated by failing to answer 9/10 questions correctly on the quiz

12. 12. Pregnant or breastfeeding

13. 13. Currently taking sympathomimetic drugs, or a thiazolidinedione antidiabetic

14. ALT and/or AST >4X upper limit of normal

15. A Child-Pugh score >7

16. Currently receiving opioids for pain management

17. In a treatment study where medication was administered in the last 30 days

18. Currently using medications that are known to be strong or moderate inhibitors of CYP2D6 such as fluoxetine, paroxetine, mirabegron, bupropion, quinidine, terbinafine, cimetidine, cinacalcet, duloxetine, or fluvoxamine

19. In a methadone maintenance or buprenorphine treatment program within the last 30 days

Related Conditions & MeSH terms

• Opiate Withdrawal Syndrome
• Opioid Use
• Substance Withdrawal Syndrome

Intervention

Drug:
• LFX/PGB
lofexidine tablets 0.18mg tabs pregabalin capsules 100mg and 25mg
• LFX/PLA-PGB
lofexidine tablets 0.18mg tabs pregabalin capsules 0mg

Locations

Country	Name	City	State
United States	Mountain Manor Treatment Center	Baltimore	Maryland
United States	University of Pennsylvania, Treatment Research Center	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Subjective Opioid Withdrawal Scale (SOWS) scores	Subjective patient reported Opioid Withdrawal measured by the SOWS, (0-30); 0 = no withdrawal/30 = severe withdrawal	10 days per subject, through study completion (N=150)
Secondary	Study detox completion	Proportion that receives one or more doses of study medication and completed withdrawal (Completing withdrawal management will be defined as having received at least 1 dose of study medication on day 8 and completing the SOWS-Gossop assessment on day 8); and proportion that transition to XR-NTX; adverse events	10 days per subject, through study completion (N=150)
Secondary	XR-NTX IM injection	proportion that receives 380mg dose of extended-release naltrexone	upto 2 days per subject (N=150)